Hero

Celyad Announces Third Quarter 2017 Business Update

1

Celyad Announces Third Quarter 2017 Business Update

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

2

Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

Celyad announces new agreements with Celdara Medical and Dartmouth College

3

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

4

Celyad reports promising early results at first dose level of the solid arm of the THINK trial

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

5

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

About Celyad

Making the Impossible Possible

Celyad is a clinical-stage biopharmaceutical that is developing next generation CAR-T NK cell-based immunotherapies for cancer treatment.

Latest News

Letter to Shareholders - December 2017

Letter to Shareholders - December 2017

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad Announces Third Quarter 2017 Business Update

Celyad Announces Third Quarter 2017 Business Update

Discover all news

Carousel

Social Feed

RT @ChristianHomsy: @CelyadSA Full schedule for two teams at #JPM2018.

1 week ago

RT @ChristianHomsy: @CelyadSA Full schedule for two teams at #JPM2018.

RT @lecho: Celyad, star de ce début 2018 https://t.co/uzWBtUVXjr

1 week ago

RT @lecho: Celyad, star de ce début 2018 https://t.co/uzWBtUVXjr

Interesting results related to #NKG2D @AACR https://t.co/xB1aKhZ4gc

3 weeks ago

Interesting results related to #NKG2D @AACR https://t.co/xB1aKhZ4gc

RT @pharmabe: L’immunothérapie est une nouvelle piste prometteuse pour lutter contre le cancer. Les chercheurs tentent de mettre au point d…

1 month ago

RT @pharmabe: L’immunothérapie est une nouvelle piste prometteuse pour lutter contre le cancer. Les chercheurs tentent de mettre au point d…

RT @ChristianHomsy: @CelyadSA Full schedule for two teams at #JPM2018.

1 week ago

RT @ChristianHomsy: @CelyadSA Full schedule for two teams at #JPM2018.

RT @lecho: Celyad, star de ce début 2018 https://t.co/uzWBtUVXjr

1 week ago

RT @lecho: Celyad, star de ce début 2018 https://t.co/uzWBtUVXjr

Interesting results related to #NKG2D @AACR https://t.co/xB1aKhZ4gc

3 weeks ago

Interesting results related to #NKG2D @AACR https://t.co/xB1aKhZ4gc

RT @pharmabe: L’immunothérapie est une nouvelle piste prometteuse pour lutter contre le cancer. Les chercheurs tentent de mettre au point d…

1 month ago

RT @pharmabe: L’immunothérapie est une nouvelle piste prometteuse pour lutter contre le cancer. Les chercheurs tentent de mettre au point d…